anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic cerebral hypoperfusion (CCH), a disease afflicting numerous individuals worldwide, is a primary cause of cognitive deficits, the pathogenesis of which remains poorly understood. Bruton's tyrosine kinase inhibition (BTKi) is considered a promising strategy to regulate inflammatory responses within the brain, a crucial process that is assumed to drive ischemic demyelination progression. However, the potential role of BTKi in CCH has not been investigated so far. In the present study, we elucidated potential therapeutic roles of BTK in both in vitro hypoxia and in vivo ischemic demyelination model. We found that cerebral hypoperfusion induced white matter injury, cognitive impairments, microglial BTK activation, along with a series of microglia responses associated with inflammation, oxidative stress, mitochondrial dysfunction, and ferroptosis. Tolebrutinib treatment suppressed both the activation of microglia and microglial BTK expression. Meanwhile, microglia-related inflammation and ferroptosis processes were attenuated evidently, contributing to lower levels of disease severity. Taken together, BTKi ameliorated white matter injury and cognitive impairments induced by CCH, possibly via skewing microglia polarization towards anti-inflammatory and homeostatic phenotypes, as well as decreasing microglial oxidative stress damage and ferroptosis, which exhibits promising therapeutic potential in chronic cerebral hypoperfusion-induced demyelination.
Hepatobiliary cancers, including hepatocellular carcinoma and cancers of the biliary tract, share high mortality and rising incidence rates. They may also share several risk factors related to unhealthy western-type dietary and lifestyle patterns as well as increasing body weights and rates of obesity. Recent data also suggest a role for the gut microbiome in the development of hepatobiliary cancer and other liver pathologies. The gut microbiome and the liver interact bidirectionally through the "gut-liver axis," which describes the interactive relationship between the gut, its microbiota, and the liver. Here, we review the gut-liver interactions within the context of hepatobiliary carcinogenesis by outlining the experimental and observational evidence for the roles of gut microbiome dysbiosis, reduced gut barrier function, and exposure to inflammatory compounds as well as metabolic dysfunction as contributors to hepatobiliary cancer development. We also outline the latest findings regarding the impact of dietary and lifestyle factors on liver pathologies as mediated by the gut microbiome. Finally, we highlight some emerging gut microbiome editing techniques currently being investigated in the context of hepatobiliary diseases. Although much work remains to be done in determining the relationships between the gut microbiome and hepatobiliary cancers, emerging mechanistic insights are informing treatments, such as potential microbiota manipulation strategies and guiding public health advice on dietary/lifestyle patterns for the prevention of these lethal tumors.
FIELD: organic chemistry, medicine, cardiology, pharmacy. SUBSTANCE: invention describes compounds of the formula (I)   and also their stereoisomers, acid-additive salts and hydrates where substituted have values given in description. Invention describes also preparing a pharmaceutical composition showing antiarrhythmic activity. Invention proposes also method of treatment of cardiac arrhythmia in mammals involving administration of antiarrhythmic amount of compound of the formula (I). EFFECT: improved method preparing, valuable medicinal properties. 6 cl, 2 dwg, 11 tbl, 39 ex
PURPOSE:To obtain a hyaluronidase activity ihibitor and an oil in water type cream base preparation therefrom, containing chondroitin sulfuric acid or its salts having a potent hyaluronidase inhibiting activity and a surface active effect. CONSTITUTION:A hyaluronidase activity inhibitor having a high safety and a good stability, containing chondroitin sulfuric acid or its salts. An oil in water type cream base preparation is obtained by combining an oil component and a water component containing chondroitin sulfuric acid or its salts (a water component containing conchiolin is especially preferable), and by emulsifying them by using a microfluidizer. The substance obtained by emulsifying the preparation containing chondroitin sulfuric acid, shows very solid creamy state and is hard to be separated. Since no surfactantis used, it is safe to the skin. It keeps moistness and flexibility of the skin, contributes to the stability of hyaluronic acid, suppresses skin inflammation, and acts also suppressivelyto allergic symptoms.
Participant will order food and beverages from three menus containing labels next to items that contain equal to or higher than half the daily value of added sugar (greater than or equal to 25 grams). The label will be on the right of the item, colored red, icon plus text design, and height that is 100% of size of the menu text height.
Thunderbeat instrument combines an advanced bipolar clamp to the existing ultrasonic cutter. In the animal study with pig, the result of Thunderbeat shows fast abalation rate and same thermal conductivity. There has been reported a significant reduction in operative time and same complications with Thunderbeat in gynecology patient who underwent laparoscopic hysterectomy with lymph node dissection. Comparison of the utilization of this new device, however, with the Harmonic scalpel in thyroidectomy has not been performed in any study. The objective of this study is to compare the results of thyroidectomy using the Thunderbeat to that with the Harmonic scalpel device in respect to hemostasis, operative time and perioperative complications. All patients undergoing a thyroidectomy in our endocrine surgery department are randomized into those operated with Thunderbeat (Group A) and those with Harmonic scalpel (Group B).
PURPOSE: A pain killer agent containing cherry extract is provided to ensure anticancer effect and pain killing effect same with aspirin without harmfulness. CONSTITUTION: A cherry extract is produced by shaking fruit of Prunus serrulata var. spontanea in distilled water at 100°C. An oral formulation contains cherry extract or antocyanin and ascorbic acid isolated from cherry extract. The antocyanin is esterified with fatty acid. The oral formulation additionally contains water-soluble antioxidant, ascorbic acid(vitamin C).
Herpes simplex virus 2 (HSV-2) causes genital herpes and increases the risk of acquisition and transmission of HIV. An HSV-2 vaccine is not available. We will study a replication-defective HSV-2 vaccine, HSV529, that is deleted for 2 essential viral proteins, that can infect, but not replicate in normal cells. The goals of the study are to determine (a) the safety of HSV529 vaccine in persons with or without HSV infection, and (b) the ability of the vaccine to elicit immune responses to HSV-2 including virus-specific antibodies and T cell responses to the virus. Three groups of 20 subjects each will be randomized and will receive 3 doses of HSV529 (15 subjects per group) or saline placebo injection (5 subjects per group). Each subject will be followed for 6 months after the last dose of vaccine. The 3 groups will be (a) subjects who were infected with HSV-2 in the past but may or may not have been infected with HSV-1 (HSV-1+/-/HSV-2+), (b) subjects who have been infected only with HSV-1 (HSV-1+/HSV-2-), and (c) subjects who have not been infected with HSV-1 or HSV-2 (HSV-1-/HSV-2-). Vaccine or placebo will be administered on Day 0 and approximately 1 month and 6 months after enrollment.
Worldwide, breast cancer is the number one cancer in women. It affects about 12% or 1.7 mln women worldwide. In Mongolia breast cancer is less common, occupies 5-th place by frequency in women, the incidence is 118 per 100,000 or 1,770 cases per year.

Many different types of immunotherapy (especially checkpoint inhibitors) are being tested, but so far the successes have been insignificant, and serious side effects are frequent and unpredictable. This Phase II will evaluate a new type of breast cancer immunotherapy based on a fundamentally new approach that has been successfully tested in a published clinical study of liver cancer. Investigators will test new tableted preparation, V3-MOMMO, obtained from hydrolyzed, inactivated blood and tumor tissues of patients with breast cancer. Study will last 3 months, 20 patients will be recruited, given one pill per day for three months. The primary clinical endpoint is effect on tumor size and lymph nodes burden after 3 months. Secondary endpoint will be effect on levels of tumor markers (i.e., cancer antigen 15-3 (CA 15-3), cancer antigen 27.29 (CA 27.29), and carcinoembryonic antigen (CEA) on monthly basis compared to baseline.
BACKGROUND: An association between granuloma annulare (GA) and dyslipidaemia has been reported. Adipophilin expression may play a plausible role as a cutaneous biomarker for dyslipidaemia in patients with GA; however, this potential link remains to be explored.
METHODS: Patients with GA were identified at our hospital between January 1, 1990, and December 31, 2021, with a thorough review of their clinical and histological characteristics. Adipophilin staining was assessed in biopsies of GA lesions.
RESULTS: A total of 107 patients with GA were included. The prevalence of dyslipidaemia in patients with positive adipophilin staining was clearly higher than in those with negative labelling (62.3% vs 13.3%). Relative to the dyslipidaemia risk for patients with negative adipophilin expression, the odds for patients with positive adipophilin expression were increased 10-fold (OR: 10.8; p-value<.01). We identified 23 incident cases of dyslipidaemia over a median follow-up period of 91 months among 54 patients with no history of dyslipidaemia. The patients with positive adipophilin expression showed a higher risk of developing dyslipidaemia (HR: 8.9; p-value<.01).
CONCLUSIONS: Patients with positive adipophilin staining in their GA biopsies were found to be associated with a higher risk for both baseline and incident dyslipidaemia.
"Stroke is a major cause of death and severe disability.The only effective, available therapy, within few hours of stroke onset, is rt-PA, a thrombolytic agent. Preliminary experience but not from properly conducted randomized trials indicates that intra-arterial treatment might be more effective than intravenous therapy for some vascular lesions. Intravenous application has not been tested directly against intra-arterial treatment and we do not known the relative clinical effectiveness with these two routes of administration. Eligible patients will be randomized to receive either IV rt-PA (0.9mg/kg; max 90 mg), 10% of which would be infused over 1 minute, and the remainder over 60 min, or IA rt-PA within the thrombus by means of microcatheter. In patients allocated to IA rt-PA the angiogram is performed as soon as possible within 6 hours of stroke onset; IV heparin has to be initiated (2000 U bolus followed by 500 U7hr infusion) and rt-PA is delivered at a rate of about 90 mg/hr for maximum one hour at the dose needed for recanalization up to 0.9 mg/Kg (max 90 mg). Antithrombotics and anticoagulants are disallowed during the first 24 hours (except heparin used during the angiogram). After 24 hrs, all patients will be considered for long-term antiplatelet or anticoagulant therapy. Follow-up will take place at 7 days, discharge, or transfer, whichever is first; and again at 3 months. 4 centers are currently authorized for the start-up phase; 15 centers in Italy have applied for an expansion phase of the study (SYNTHESIS EXPANSION), with financial support from Italian National Agency for Drugs (AIFA).The two phases of the study will be analysed separately and will be considered in a pooled analysis.
Migraine headaches can be disabling and can interfere with work and a person's quality of life. Preventing these headaches before they start is the best option. Topiramate, an anti-seizure medication, has been shown to help prevent migraine headaches from occurring. This is an open-label study that is an extension of a previous study (CAPSS-276) of Topiramate in chronic migraine. It includes patients who completed the previous study or who stopped the study early after taking study drug for at least 4 weeks of maintenance treatment due to lack of efficacy. The current study will involve a 4-week Blinded Transition Phase during which patients will be titrated up to a daily topiramate dose of 100 milligrams (or the maximum tolerated dose, whichever is less). Then there will be a 12-week Open-Label Maintenance Phase during which the topiramate dose may be adjusted according to effectiveness and tolerance, but not to exceed a daily dose of 400 milligrams. After this period, patients will be tapered off topiramate (Taper/Exit Phase). The length of the taper/exit phase may vary based on the dose the patient was taking during the open label maintenance phase. While on topiramate, patients will record daily entries in their headache records. Patients will also be asked questions to help assess their quality of life. Both patients and doctors will be asked questions at the end of the study about their impressions of change with respect to the patient's migraine headaches. Patients will also have physical and neurological examinations and laboratory tests performed during the study. The objective of this study is to evaluate the long-term safety and effectiveness of topiramate for the prevention of chronic migraine headaches. Topiramate oral tablets, 25 milligrams per tablet, will be given in the morning and evening to a dose not to exceed 400 milligrams per day or to the maximum tolerated dose, whichever is less
A composition for cosmetics is provided, which has a UV shielding effect and which can produce a cosmetic having good dispersibility, an excellent UV shielding effect and excellent use feeling, cosmetic effect, long-lasting cosmetic performance. The cosmetic obtained by using the same is provided. The composition for cosmetics includes (A) microparticulate titanium dioxide, (B) one kind or two or more kinds of magnesium hydroxide and calcium hydroxide. The composition for cosmetics preferably contains further (C) a clay mineral. The compounding weight ratio among (A):(B):(C) is preferably 20 to 60:3 to 40:0 to 77. In addition, the composition for cosmetics is preferably one in which a mixed powder of (A), (B) and (C) is lipophilically treated.
The invention relates to a method for producing a retrievable hair restyling. To this end, a composition is applied on the hair (5), said composition containing at least one active ingredient or an active ingredient mixture which can provide a shape memory effect by itself or in combination with other substances after being applied to the hair and after performing the inventive treatment of the hair. The composition additionally contains at least a second active ingredient, namely a hydrophobic substance with a water solubility of  = 5 percent by weight at 20 °C. The hair is arranged in a given (permanent) shape and said permanent shaped is then fixed by inducing a chemical or physical modification of the applied active ingredients, wherein after a wanted or unwanted deformation of the shape memory, the original shape memory can be restored by means of a physical simulation. In addition to the permanent hairstyle, a second (temporary) shape can be styled. The invention also relates to a method for restoring a previously programmed permanent hairstyle that can be transformed into a temporary shape or was deformed.
The study was conducted at a specialist National Health Service (NHS) mental health service for refugees, asylum seekers and forced migrants suffering from Post-Traumatic Stress Disorder (PTSD). Four participants were enrolled in the study. This was initially intended to be a larger study (n=15) but recruitment stopped due to the COVID-19 pandemic and advice from the trust R\&D and NHS service manager that face-to-face appointments should no longer go ahead at the NHS clinical recruitment site. The trust R\&D advised that only participants who had started the intervention should continue and only if done remotely. An amendment was approved for remote delivery of the intervention. Two of the four participants who gave informed consent continued to participate in the study. They met with a researcher remotely via video technology. The other two participants instead continued to receive standard care by the NHS service but did not continue with the research study. This study was a pilot.

The study had a multiple baseline case-series design (AB), with a randomised duration of baseline length up to three weeks. At the start of the baseline phase, participants created, with the help of the researcher, a list of their most frequent and distressing intrusive memories of trauma. Each intrusive memory was given a label (for example; a letter, colour or symbol) so that the frequency of each intrusive memory could be monitored in a pen and paper diary. The frequency of specific intrusive memories the person experienced after they had received the intervention will be compared to the frequency of specific intrusive memories they had during the baseline phase. For each specific intrusion, the period prior to that intrusion being targeted in an intervention session was the baseline phase (A); therefore, the baseline phase included the minimum baseline duration (lasting up to three weeks) plus the additional weeks in which the specific intrusion remained untargeted by the intervention. The post intervention phase (B) was the time after the specific intrusion was targeted. Some intrusive memories on the list were not targeted by the intervention but were monitored (through the intrusion diary) throughout the duration of the study for comparison.

This study was a follow-up to a study conducted in Sweden with refugees. ClinicalTrials.gov Identifier: NCT03760601. The research is extending the previous research to refugees and asylum seekers with a diagnosis of PTSD, accessing a secondary care mental health service and living in the United Kingdom (UK).
PURPOSE:To obtain a hypotensor having excellent potassium channel activation activity by using a specific thiazolo[5,4-b]azepine derivative as an active component. CONSTITUTION:The objective agent contains, as an active component, a compound of formula I (R<1> is H, aliphatic group, carboxylic acid acyl or sulfonic acid acyl each of which may have substituents; R<2> is H, aromatic group or aliphatic group each of which may have substituents) or its salt, e.g. 2-(4- chlorostyryl)-5,6,7,8-tetrahydro-4H-thiazolo[5,4-b]azepine. The compound is useful as a remedy for circulatory diseases of mammals such as hypertension or stenocardia. It is administered twice or thrice a day for adult preferably at a rate of 0.5-20mg per dose in the case of oral administration or 0.3-10mg per dose in the case of parenteral administration. The compound of formula I can be produced by reacting a compound of formula II with a reactive derivative of carboxylic acid of formula R<2>COX and treating the resultant compound of formula III with a sulfurizing agent.
FIELD: organic chemistry. SUBSTANCE: products: derivatives of benzimidazole, mixture of their isomers or individual isomers and their acid-additive salts showing pharmacological activity. Benzimidazole derivatives have the general formula (I) given in description. Also, all meanings of radicals were given. Synthesized compounds were used as angiotensin II antagonists. EFFECT: improved method of synthesis and effectiveness of compounds indicated above. 2 cl
PROBLEM TO BE SOLVED: To obtain a new nitromethylsulfonamide derivative capable of exhibiting excellent aldose reductase-inhibiting action and preventing and treating effect of diabetic complication. SOLUTION: This nitromethylsulfonamide derivative is represented by formula I (A is an aryl or heterocyclic group; and R1 is H or an alkyl) or its pharmaceutically permissible salt, e.g. nitromethylsulfonamide. The derivative of formula I can be synthesized by reacting the corresponding amine derivative with methanesulfonyl chloride in the presence of an organic base, reacting the resultant methylsulfonamide derivative of formula II with an alkyl nitrate in the presence of a strong base and as necessary, further, reacting the reaction product with a base or an acid. The derivative of formula I is included as an active ingredient to provide the objective preventing or therapeutic agent for diabetic complication, which can prevent and treat, e.g. diabetic cataract, diabetic retinopathy, diabetic corneopathies, diabetic nephropathy, etc.
PROBLEM TO BE SOLVED: To obtain a new polynucleotide having high identity with a nucleic acid encoding HKABY 60 polypeptide having a specific amino acid sequence, and usable in e.g. the therapeutic protocol design and diagnosis of cancers, inflammatory diseases, immune diseases and viral diseases. SOLUTION: This new polynucleotide is an isolated polynucleotide containing a nucleotide sequence with >=80% identity with the whole length of a nucleotide sequence encoding HKABY 60 polypeptide of the formula, or containing a nucleotide sequence complementary to the above. This new polynucleotide is useful in e.g. the therapeutic protocol design and diagnosis of cancers, inflammatory diseases, immune diseases and viral disease. This new polynucleotide is obtained from a cDNA library derived from mRNA in dendritic cell origin, prostate gland, skin, fetal liver and splenocytes by employing expression sequence tag(EST) analysis using the standard cloning and screening techniques.
OBJECTIVE: To compare the prognostic power of Hounsfield units (HU) and Vertebral Bone Quality (VBQ) score for predicting proximal junctional kyphosis (PJK) following long-segment thoracolumbar fusion to the upper thoracic spine (T1-T6).
METHODS: Vertebral bone quality around the upper instrumented vertebrae (UIV) was measured using HU on preoperative CT and VBQ on preoperative MRI. Spinopelvic parameters were also categorized according to the Scoliosis Research Society-Schwab classification. Univariable analysis to identify predictors of the occurrence of PJK and survival analyses with Kaplan-Meier method and Cox regression were performed to identify predictors of time to PJK (defined as ≥10° change in Cobb angle of UIV+2 and UIV). Sensitivity analyses showed thresholds of HU < 164 and VBQ > 2.7 to be most predictive for PJK.
RESULTS: Seventy-six patients (mean age 66.0 ± 7.0 years; 27.6% male) were identified, of whom 15 suffered PJK. Significant predictors of PJK were high postoperative pelvic tilt (P = 0.038), high postoperative T1-pelvic angle (P = 0.041), and high postoperative PI-LL mismatch (P = 0.028). On survival analyses, bone quality, as assessed by the average HU of the UIV and UIV+1 was the only significant predictor of time to PJK (odds ratio [OR] 3.053; 95% CI 1.032-9.032; P = 0.044). VBQ measured using the UIV, UIV+1, UIV+2, and UIV-1 vertebrae approached, but did not reach significance (OR 2.913; 95% CI 0.797-10.646; P = 0.106).
CONCLUSIONS: In larger cohorts, VBQ may prove to be a significant predictor of PJK following long-segment thoracolumbar fusion. However, Hounsfield units on CT have greater predictive power, suggesting preoperative workup for long-segment thoracolumbar fusion benefits from computed tomography versus magnetic resonance imaging alone to identify those at increased risk of PJK.